Onureg (azacitidine) — Highmark
Acute myeloid leukemia (AML)
Initial criteria
- age ≥ 18 years
- Diagnosis of acute myeloid leukemia (AML)
- Member achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy
- Prescriber attests that the member is unable to complete intensive curative therapy
Reauthorization criteria
- Prescriber attests that the member is tolerating therapy and has experienced a therapeutic response defined as one of the following:
- Disease improvement
- Delayed disease progression
Approval duration
12 months